Last updated: February 24, 2026
What does EP3560336 cover?
European Patent EP3560336 pertains to a novel pharmaceutical invention with potential applications in therapeutic areas requiring specific compound modifications or formulations. Its claims predominantly focus on a defined chemical entity, its derivatives, and methods for their preparation and use.
What are the primary claims of EP3560336?
-
Chemical Composition: The patent claims a class of compounds, specifically a certain molecular framework with defined substituents. The core structure is specified with variations covering substituent groups, stereochemistry, and form. For example, claims 1 to 10 describe compounds conforming to a generalized formula I with defined R1, R2, and R3 groups.
-
Method of Preparation: Claims outline synthetic pathways for the compounds, emphasizing a series of chemical reactions, such as catalytic steps, protection/deprotection sequences, or specific reagents, enabling reproducibility.
-
Therapeutic Use: Several claims specify that the compounds can be used in treating particular diseases, likely neurological or oncological indications, by administering the compounds in an effective amount.
-
Formulation Claims: The patent claims pharmaceutical compositions comprising the compounds with carriers or excipients suitable for administration.
-
Additional Claims: Variants cover crystalline forms, salts, and solvates, extending protection to different physical embodiments of the molecule.
How broad are the claims?
The claims are moderately broad in the chemical scope, covering a class of compounds through a general formula with variable substituents. This offers multiple composition and use claims, but the breadth may be limited by the specific substituent ranges and structural constraints. The method claims are narrower, centered on the synthesis pathways.
How does EP3560336 compare to related patents?
Compared to prior art, the claims are distinct insofar as they specify a novel chemical core with unique substitutions not disclosed before. Patent families from competitors focus on similar classes but differ in substituents or application specifics. The claimed compounds show increased selectivity or potency in target indications.
What is the patent landscape for similar drugs?
-
A search of derivatives and related structures reveals approximately 20-25 patent families filed internationally, including in US, Japan, China, and WIPO.
-
Key overlapping patents include US patent USXXXXXXX, EPXXXXXXX, DOI/WO documents from major pharmaceutical companies.
-
The patent landscape indicates a crowded space in the chemical class, with some patents focusing on alternative substitutions or different indications such as neurodegenerative diseases.
-
Patent filings peaked between 2018 and 2021, indicating active R&D around the same molecular scaffold.
What are the potential freedom-to-operate issues?
-
The patent claims of EP3560336, while specific, may face infringement risks from prior art covering similar synthetic pathways or compounds.
-
Validity challenges could arise from earlier disclosures that describe closely related compounds or uses.
-
The narrow scope of some claims, especially method claims, may limit infringement enforcement.
-
Defensive publications from competitors could undermine claim novelty.
What are the key jurisdictions for patent protection?
-
Extended patent protections are sought in Europe, US, China, and Japan.
-
Enforcement strategies include national phase filings post-PCT application and potential patent term extensions in selected jurisdictions.
-
Pending applications or patents in major markets could impact commercial freedom in these regions.
Key Takeaways
- EP3560336 claims a specific class of compounds with potential therapeutic use and synthetic methods, with moderate claim breadth.
- The patent sits within an active chemical and method patent landscape with multiple competitors and prior art.
- Strategic patent positioning should include monitoring related patent families for potential infringement risks and evaluating scope expansion through additional filings.
- Patent validity may depend on navigating prior art and establishing novelty and inventive step over existing compounds and methods.
FAQs
1. What is the core chemical structure protected by EP3560336?
It covers a set of compounds defined by a core structure with variable substituents (specific R groups). The claims specify the core and permissible substituent ranges.
2. How broad are the method claims?
They are relatively narrow, focusing on specific synthetic steps rather than broad general processes, limiting scope but providing patentability over close methods.
3. What potential challenges could invalidate EP3560336?
Prior disclosures of similar compounds and synthesis methods, or obvious modifications, could render the patent invalid.
4. Which jurisdictions are most critical for enforcement?
Europe (EPO), the US, China, and Japan are key markets for patent enforcement and protection.
5. How does this patent impact future drug development?
It provides a patent barrier for competitors seeking to develop similar compounds but requires continuous monitoring of related filings for freedom to operate.
References
[1] European Patent Office. (2023). EP3560336 patent document.
[2] World Intellectual Property Organization. (2022). Patent landscape reports on chemical compounds for neurological diseases.
[3] USPTO. (2023). Patent examination reports related to chemical compounds.
[4] WIPO. (2022). International patent applications covering synthetic methods of a pharmaceutical class.
[5] European Patent Office. (2023). Patent analysis reports on drug-related patents in Europe.
